Tyrosine kinase inhibitors against the epidermal growth factor receptor (EGFR) have been developed and although the vast majority of patients with lung cancer failed to respond, a minority showed dramatic tumor shrinkage. The gene discussed is EGFR; the disease is neoplasm.